


## Beth Israel Lahey Health GLP-1RA Conversion Guide

The purpose of this guide is to assist with the conversion of GLP-1 RAs due to current product shortages. Patients may have limited or intermittent access to one or more of these agents. Please see the [FDA Drug Shortages website](#) for up-to-date information on specific dose availability. Assessment of equivalent dose is based on head-to-head clinical trials when available and/or clinical experience. This guide does not replace clinical judgment.

### GLP-1 Receptor Agonist Suggested Comparative Doses for Treating Type 2 Diabetes

Agent	Dosing Route and Interval	Comparative Doses							
Liraglutide <sup>1</sup>	SC weekly	0.6 mg	1.2 mg	1.8 mg					
Exenatide XR	SC weekly			2 mg					
Dulaglutide <sup>1</sup>	SC weekly		0.75 mg	1.5 mg	3 mg	4.5 mg			
Semaglutide <sup>1</sup>	SC weekly		0.25 mg	0.5 mg		1 mg	2 mg		
Semaglutide	PO daily	3 mg	7 mg	14 mg					
Tirzepatide	SC weekly			2.5 mg		5 mg	7.5 mg	10 mg	12.5 mg 15 mg

<sup>1</sup> Agents with proven ASCVD evidence



## Summary of Clinical Evidence and Comparison Chart

Trial	Active Comparators	Background Regimen	Time Point for efficacy, weeks	A1c reduction	Weight loss, kg	Adverse Effects: D/C due to GI adverse events
Award 11	Trulicity 1.5 mg vs. Trulicity 3 mg	Metformin	36	Trulicity 1.5 mg: -1.5% Trulicity 3 mg: -1.6% not statistically sig	-8.4 lbs (3 mg)	3.1%
Award 11	Trulicity 1.5 mg vs. Trulicity 4.5 mg	Metformin	36	Trulicity 4.5 mg: -1.8% P <0.001	-10.1 lbs (4.5 mg)	3.1%
SUSTAIN 7	Ozempic 1 mg vs. Trulicity 1.5 mg	Metformin	40	Ozempic 1 mg: -1.6% Trulicity 1.5 mg: -1.3% p=0.0004	Ozempic 1 mg: -12.8 lbs Trulicity 1.5 mg: -6.2 lbs	6% (vs. 5% Trulicity)
SUSTAIN FORTE	Ozempic 1 mg vs. Ozempic 2 mg	Metformin +/- SFU	40	Ozempic 1 mg: -1.9% Ozempic 2 mg: -2.1% P < 0.01	Ozempic 2 mg: -14.2 lbs Ozempic 1 mg: -12.5 lbs	Not documented. Nausea 14% vs. 15%
SURPASS-2	Ozempic 1 mg vs. Mounjaro 5 mg, 10 mg, 15 mg	Metformin	40	Mounjaro 5 mg: -2% Mounjaro 10 mg: -2.2% Mounjaro 15 mg: -2.3% Ozempic 1 mg: -1.9%	Mounjaro 5 mg: -17 lbs Mounjaro 10 mg: -21 lbs Mounjaro 15 mg: -25 lbs Ozempic 1 mg: -13 lbs	Mounjaro 5 mg: 2.8% Mounjaro 10 mg: 4.3% Mounjaro 15 mg: 4.3% Ozempic 1 mg: 3.2%

### References:

- Almandoz J, Lingvay I, Morales J et al. Switching between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. *Clin Diabetes*. 2020; 38 (4):390-402.
- Frias, Juan P., et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). *Diabetes Care*. 2021; 44(3): 765-773.
- Pratley RE, Aroda VR, Lingvay I, et al, on behalf of the SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *Lancet Diabetes Endocrinol*. 2018;6(4):275-286.
- Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. *Lancet Diabetes Endocrinol*. 2021;9(9):563-574.
- Frías JP, Davies MJ, Rosenstock J, et al.; for the SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. *N Engl J Med*. 2021;385(6 suppl):503-515
- Whitley HP, Trujillo JM, Neumiller JJ. Special report: potential strategies for addressing glp-1 and dual glp-1/gip receptor agonist shortages. *Clinical Diabetes*. 2023;41(3):467-473.